210 related articles for article (PubMed ID: 30301398)
1. Re-examining insulin compared to non-insulin therapies for type 2 diabetes: when in the disease trajectory is insulin preferable?
Mishriky BM; Cummings DM; Tanenberg R; Pories WJ
Postgrad Med; 2018 Nov; 130(8):653-659. PubMed ID: 30301398
[TBL] [Abstract][Full Text] [Related]
2. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
Weng J
J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
[TBL] [Abstract][Full Text] [Related]
3. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
Vinik A
Clin Ther; 2007 Jun; 29(6 Pt 1):1236-53. PubMed ID: 18036387
[TBL] [Abstract][Full Text] [Related]
4. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
Vinik A
Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925
[TBL] [Abstract][Full Text] [Related]
5. Importance of glucose control.
Edelman SV
Med Clin North Am; 1998 Jul; 82(4):665-87. PubMed ID: 9706116
[TBL] [Abstract][Full Text] [Related]
6. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.
Emanuele N; Klein R; Abraira C; Colwell J; Comstock J; Henderson WG; Levin S; Nuttall F; Sawin C; Silbert C; Lee HS; Johnson-Nagel N
Diabetes Care; 1996 Dec; 19(12):1375-81. PubMed ID: 8941467
[TBL] [Abstract][Full Text] [Related]
7. [Improvement in glycemic control, cardiovascular risk factors and anthropometric data in type 2 diabetic patients after the switch from biphasic human insulin to biphasic premix analog insulin aspart].
Gero L; Gyimesi A; Hidvégi T; Jánosi I
Orv Hetil; 2009 Aug; 150(35):1637-47. PubMed ID: 19692308
[TBL] [Abstract][Full Text] [Related]
8. Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.
Schwartz SS; Jellinger PS; Herman ME
Postgrad Med; 2016 Aug; 128(6):609-19. PubMed ID: 27210018
[TBL] [Abstract][Full Text] [Related]
9. Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes: a review.
Dailey G
Curr Med Res Opin; 2004 Dec; 20(12):2007-14. PubMed ID: 15701217
[TBL] [Abstract][Full Text] [Related]
10. Treatment of the patient with diabetes: importance of maintaining target HbA(1c) levels.
Davidson JA
Curr Med Res Opin; 2004 Dec; 20(12):1919-27. PubMed ID: 15701210
[TBL] [Abstract][Full Text] [Related]
11. Insulin initiation and intensification: insights from new studies.
Kumar A; Kalra S
J Assoc Physicians India; 2011 Apr; 59 Suppl():17-22. PubMed ID: 21818994
[TBL] [Abstract][Full Text] [Related]
12. Emerging care for type 2 diabetes: using insulin to reach lower glycemic goals.
Feinglos MN; Bethel MA
Cleve Clin J Med; 2005 Sep; 72(9):791-9. PubMed ID: 16193826
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
14. Issues surrounding tight glycemic control in people with type 2 diabetes mellitus.
Cerveny JD; Leder RD; Weart CW
Ann Pharmacother; 1998 Sep; 32(9):896-905. PubMed ID: 9762378
[TBL] [Abstract][Full Text] [Related]
15. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
[TBL] [Abstract][Full Text] [Related]
16. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus.
Henry RR
Ann Intern Med; 1996 Jan; 124(1 Pt 2):97-103. PubMed ID: 8554221
[TBL] [Abstract][Full Text] [Related]
17. Insulin therapy in type 2 diabetes.
Mudaliar S; Edelman SV
Endocrinol Metab Clin North Am; 2001 Dec; 30(4):935-82. PubMed ID: 11727406
[TBL] [Abstract][Full Text] [Related]
18. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
[TBL] [Abstract][Full Text] [Related]
20. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM.
Colwell JA
Ann Intern Med; 1996 Jan; 124(1 Pt 2):131-5. PubMed ID: 8554205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
